Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Part
Fiche publication
Date publication
mai 2010
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, Mascaux C, Meert AP, Roelandts M, Scherpereel A, Terrones Munoz V, Sculier JP,
Lien Pubmed
Résumé
Few validated prognostic factors are available for survival in patients with lung cancer. [F]-fluoro-2-deoxy-d-glucose positron emission tomography has been shown to be of additional value to conventional imaging for staging lung cancer. The prognostic value of this lung tumor metabolic activity was studied in a first systematic review of studies published until 2006.
Mots clés
Carcinoma, Non-Small-Cell Lung, diagnosis, Clinical Trials as Topic, Fluorodeoxyglucose F18, pharmacokinetics, Humans, Lung Neoplasms, diagnosis, Positron-Emission Tomography, Prognosis, Radiopharmaceuticals, pharmacokinetics, Survival Rate
Référence
J Thorac Oncol. 2010 May;5(5):612-9